Indu Kohaar

Program Director, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health
“my views are my own”

[Dr. Anthony Letai @NCIDirector]

This July, @theNCI is convening the Precision in Practice workshop on functional precision medicine — an approach with real potential to improve how we guide cancer treatment decisions and patient care. I hope you’ll join me for this hybrid event July 1–2. https://t.co/aMgGTBIpO4

[Eric Topol @EricTopol]

A new feature @ScienceMagazine on the clusters of cells that enhance the spread of cancer, and what can be done to break them up @ScienceVisuals
https://t.co/xNAOF834mU

[Dr. Anthony Letai @NCIDirector]

Pancreatic cancer is often found too late. @NIH- and @theNCI-supported research identified a four-marker blood panel with potential to detect it earlier. A great example of public investment in biomedical research that improves survival and offers hope. https://t.co/eOEsZTRlq6

[Cell Press @CellPressNews]

An update to the Hallmarks of Cancer framework for understanding (and researching) what causes human cancers. https://t.co/3d6pYrcAJ5

Douglas Hanahan
@CellCellPress

[United Nations @UN]

Today, the UN family mourns the loss of Dr. Jane Goodall.

The scientist, conservationist and UN Messenger of Peace worked tirelessly for our planet and all its inhabitants, leaving an extraordinary legacy for humanity and nature.

[NIH Funding @NIHFunding]

Notice of Short-Term Extension to Early-Stage Investigator (ESI) Eligibility Period https://t.co/lWeFj7KkRX

[EDRN DMCC @EDRNDMCC]

Our 14th EDRN Scientific Workshop is under way in Gaithersburg, MD! Lots to learn and share with all of our collaborators.

[EDRN DMCC @EDRNDMCC]

Speaking at the EDRN workshop, Dr. Wendel Jones of the Massive Analysis & Quality Control Society (https://t.co/aDh9WkZNl9) discussed developing best practices for using AI/ML tools in biomedical diagnostic research, like aspects of traceability & reliability.

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

Human Tumor Atlas Network

A collection of research articles, methods and datasets from a collaborative initative tracking human tumor evolution in space and time

https://t.co/iUvLobeVpV

[Nature Methods @naturemethods]

A new Perspective outlines the datasets, data standards, infrastructure, governance and community engagement approaches of the Human Tumor Atlas Network. #HTAN

https://t.co/bAd6NtTBxU

[Indu Kohaar @InduKohaar]

A Brief Look Back at 2024, With a Glimpse Into 2025 : efforts to support and inform the extramural biomedical research community on NIH grant policies and initiatives.
https://t.co/oknizXGJa9

[National Cancer Institute @theNCI]

Researchers: Can you trust your #AI model to perform well, even across diverse #DataSets? Investigators from NCI’s Center for Cancer Research recently asked this question, and here's what they learned. https://t.co/cV2eOyNZI1 #ProstateCancer

[Indu Kohaar @InduKohaar]

FDA Proposes Framework to Advance Credibility of AI Models Used for Drug and Biological Product Submissions https://t.co/kRjfFzx5eN

[Indu Kohaar @InduKohaar]

Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology https://t.co/q8rKkUXaqs

[Dr. Anthony Letai @NCIDirector]

If you like learning about AI changing cancer care, listen to this episode from @GovCIOMedia’s Cancer HealthCast about @theNCI’s AI Resource program, which enables researchers to build AI models that help better detect and treat cancer through imaging. https://t.co/ovei9CpznU

[EDRN DMCC @EDRNDMCC]

The Early Detection Research Network (EDRN) is hosting its 14th Scientific Workshop: Unleashing the Power of Collaboration – The Future is Here. This event is in-person only, March 4-6, 2025 in Gaithersburg, Maryland. Registration required, info here: https://t.co/aPUuigL1mb

[National Cancer Institute @theNCI]

What a year it’s been for #CancerResearch! ⤵️

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected #ProstateCancer

https://t.co/oIuyMVjh7u

This cohort study assessed the safety of omitting prostate biopsy (PB) in men with suspected prostate cancer who had negative multiparametric MRI (mpMRI) results. Among 593 men studied, 48% had negative MRI results, and 86% of these men avoided biopsy over a 3-year period with ongoing clinical monitoring. After 3 years, only 4% of men with negative MRI results were diagnosed with clinically significant prostate cancer (csPCa).

The findings suggest that prebiopsy MRI has a high negative predictive value, allowing men with negative MRI results to safely avoid PB when they are closely monitored. This approach supports the use of MRI to reduce unnecessary biopsies without compromising cancer detection.

@Charlie_Charite
@AsbachP
@IvoSc
@CashHannes

[Prostate Cancer Foundation @PCFnews]

🎯 The VA-MAPP (Multi-OMICS Analysis Platform for Prostate Cancer) is here! This powerful platform can be used for research on incidence, disparities, novel detection methods, treatment patterns, biomarker development, and more - https://t.co/i6XHY4p7HF

[Indu Kohaar @InduKohaar]

@hoperugo @MaryFengMD @nlinmd @UCSFCancer @OncoAlert @OncBrothers @ASCO May he rests in peace!